
Andreas J Flammer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3052799/publications.pdf Version: 2024-02-01



ANDREAS | FLAMMED

#	Article	IF	CITATIONS
1	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. Cardiovascular Research, 2022, 118, 2385-2396.	1.8	14
2	Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis. ESC Heart Failure, 2022, 9, 1186-1194.	1.4	2
3	Renal effects of guidelineâ€directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology</scp> . European Journal of Heart Failure, 2022, 24, 603-619.	2.9	57
4	The use of serotonin reuptake inhibitors increases the risk of bleeding in patients with assist devices. BMC Cardiovascular Disorders, 2022, 22, 121.	0.7	0
5	Improved survival of left ventricular assist device carriers in <scp>Europe</scp> according to implantation eras: results from the <scp>PCHFâ€VAD</scp> registry. European Journal of Heart Failure, 2022, 24, 1305-1315.	2.9	10
6	Heart failure epidemiology and treatment in primary care: a retrospective crossâ€sectional study. ESC Heart Failure, 2021, 8, 489-497.	1.4	11
7	Prognostic Value of Quantitative Metrics From Positron Emission Tomography in Ischemic HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 454-464.	2.3	16
8	Heart failure in COVIDâ€19: the multicentre, multinational PCHFâ€COVICAV registry. ESC Heart Failure, 2021, 8, 4955-4967.	1.4	26
9	Long-term follow-up after cardiac resynchronization therapy-optimization in a real-world setting: A single-center cohort study. Cardiology Journal, 2021, 28, 728-737.	0.5	2
10	Treatment of Advanced Heart Failure—Focus on Transplantation and Durable Mechanical Circulatory Support. Heart Failure Clinics, 2021, 17, 697-708.	1.0	2
11	Effects of hemodialysis on blood volume, macro- and microvascular function. Microvascular Research, 2020, 129, 103958.	1.1	1
12	Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis, 2020, 314, 58-62.	0.4	213
13	Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a longâ€ŧerm retrospective cohort study. ESC Heart Failure, 2020, 7, 2773-2783.	1.4	4
14	Clinical benefits and safety of renal denervation in severe arterial hypertension: A longâ€ŧerm followâ€up study. Journal of Clinical Hypertension, 2020, 22, 1854-1864.	1.0	7
15	Electron microscopy of SARS-CoV-2: a challenging task – Authors' reply. Lancet, The, 2020, 395, e100.	6.3	64
16	Endothelial cell infection and endotheliitis in COVID-19. Lancet, The, 2020, 395, 1417-1418.	6.3	5,100
17	Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Medical Weekly, 2020, 150, w20364.	0.8	10
18	Erythropoietin response to anaemia in heart failure. European Journal of Preventive Cardiology, 2019, 26. 7-17.	0.8	15

Andreas J Flammer

#	Article	IF	CITATIONS
19	Cardiac implantable electronic devices with a defibrillator component and allâ€cause mortality in left ventricular assist device carriers: results from the PCHFâ€VAD registry. European Journal of Heart Failure, 2019, 21, 1129-1141.	2.9	27
20	Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a <i>continuum</i> ?. European Journal of Heart Failure, 2019, 21, 988-997.	2.9	20
21	Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematological Oncology, 2019, 37, 595-600.	0.8	28
22	Characterizing cardiac involvement in amyloidosis using cardiovascular magnetic resonance diffusion tensor imaging. Journal of Cardiovascular Magnetic Resonance, 2019, 21, 56.	1.6	37
23	Ageâ€dependent impairment of the erythropoietin response to reduced central venous pressure in HFpEF patients. Physiological Reports, 2019, 7, e14021.	0.7	1
24	Myocardial triglycerides in cardiac amyloidosis assessed by proton cardiovascular magnetic resonance spectroscopy. Journal of Cardiovascular Magnetic Resonance, 2019, 21, 10.	1.6	9
25	Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction. Physiological Reports, 2019, 7, e14222.	0.7	6
26	Pulsatile arterial blood pressure mimicking aortic valve opening during continuous-flow LVAD support: a case report. Journal of Cardiothoracic Surgery, 2019, 14, 219.	0.4	4
27	Right Ventricular Failure: Pathophysiology, Diagnosis and Treatment. Cardiac Failure Review, 2019, 5, 140-146.	1.2	85
28	Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy. BMJ Open Respiratory Research, 2018, 5, e000277.	1.2	16
29	Long-term Outcomes of Kidney Transplantation in Fabry Disease. Transplantation, 2018, 102, 1924-1933.	0.5	18
30	Retinal microvascular dysfunction in heart failure. European Heart Journal, 2018, 39, 47-56.	1.0	91
31	Retinal microvascular dysfunction in hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 1523-1531.e2.	0.6	22
32	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	1.6	117
33	Polyphenols: Anti-Platelet Nutraceutical?. Current Pharmaceutical Design, 2018, 24, 146-157.	0.9	14
34	Reply to Letter to the Editor "Endothelial dysfunction in Takotsubo syndrome― International Journal of Cardiology, 2017, 234, 102.	0.8	0
35	True Anemia―Red Blood Cell Volume Deficit―in Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	16
36	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2017, 19, 821-836.	2.9	252

#	Article	IF	CITATIONS
37	Prognostic value of mean pulmonary artery pressure in the stable phase after heart transplantation. European Journal of Cardio-thoracic Surgery, 2017, 52, 775-780.	0.6	5
38	Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy?. European Journal of Heart Failure, 2017, 19, 971-973.	2.9	11
39	SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. Ophthalmologica, 2017, 238, 205-216.	1.0	12
40	Endothelial dysfunction in cardiovascular disease and Flammer syndrome—similarities and differences. EPMA Journal, 2017, 8, 99-109.	3.3	68
41	Effect of cardiac resynchronization therapy in patients with diabetes randomized in <scp>EchoCRT</scp> . European Journal of Heart Failure, 2017, 19, 80-87.	2.9	5
42	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus) Tj ETQq0 0 0 38, 3282-3292.	rgBT /Ovei 1.0	rlock 10 Tf 50
43	Cocoa, Blood Pressure, and Vascular Function. Frontiers in Nutrition, 2017, 4, 36.	1.6	68
44	Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Clinical Cardiology, 2016, 39, 285-290.	0.7	8
45	Cardiac amyloidosis: still challenging. European Heart Journal, 2016, 38, ehw290.	1.0	2
46	Successful transplantation of a donor heart with multiple traumatic defects. European Heart Journal, 2016, 37, 120-120.	1.0	1
47	Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss Medical Weekly, 2016, 146, w14295.	0.8	7
48	Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis. International Journal of Cardiology, 2015, 181, 57-64.	0.8	28
49	The primary vascular dysregulation syndrome: implications for eye diseases. EPMA Journal, 2013, 4, 14.	3.3	226
50	The eye and the heart. European Heart Journal, 2013, 34, 1270-1278.	1.0	296
51	Endothelial dysfunction over the course of coronary artery disease. European Heart Journal, 2013, 34, 3175-3181.	1.0	251
52	Refractoriness to the Effect of Endothelin-1 in Porcine Ciliary Arteries. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 488-492.	0.6	3
53	Psoriasis and atherosclerosis: two plaques, one syndrome?. European Heart Journal, 2012, 33, 1989-1991.	1.0	54
54	Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. European Heart Journal, 2012, 33, 1589-1597.	1.0	70

Andreas J Flammer

#	Article	IF	CITATIONS
55	Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. European Heart Journal, 2012, 33, 2172-2180.	1.0	104
56	Reconstituted HDL in Acute Coronary Syndromes. Cardiovascular Therapeutics, 2012, 30, e51-7.	1.1	36
57	Retinitis pigmentosa and ocular blood flow. EPMA Journal, 2012, 3, 17.	3.3	58
58	Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and Hypertension. Current Hypertension Reports, 2012, 14, 304-309.	1.5	40
59	The Assessment of Endothelial Function. Circulation, 2012, 126, 753-767.	1.6	952
60	Cocoa, Blood Pressure, and Vascular Function. Current Hypertension Reports, 2012, 14, 279-284.	1.5	21
61	Response to Letter Regarding Article, "Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease― Circulation, 2011, 123, .	1.6	Ο
62	Human endothelial dysfunction: EDRFs. Pflugers Archiv European Journal of Physiology, 2010, 459, 1005-1013.	1.3	86
63	Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease. Circulation, 2010, 122, 1789-1796.	1.6	146
64	Cocoa and Cardiovascular Health. Circulation, 2009, 119, 1433-1441.	1.6	347
65	The vascular endothelium in hypertension: target and promoter?. Hot Topics in Cardiology, 2009, , .	0.0	2
66	Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis. Circulation, 2008, 117, 2262-2269.	1.6	108
67	Response to Letter Regarding Article, "Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis― Circulation, 2008, 118, .	1.6	Ο
68	Dark Chocolate Improves Coronary Vasomotion and Reduces Platelet Reactivity. Circulation, 2007, 116, 2376-2382.	1.6	215
69	Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. Journal of Hypertension, 2007, 25, 785-791.	0.3	78
70	C-reactive protein influences shear stress-dependent platelet adhesion in patients with familiar hypercholesterolemia and coronary artery disease undergoing LDL apheresis. Thrombosis and Haemostasis, 2006, 96, 540-2.	1.8	3
71	Cardiac amyloidosis. Cardiovascular Medicine(Switzerland), 0, , .	0.1	1
72	Cardiac amyloidosis. Cardiovascular Medicine(Switzerland), 0, , .	0.1	0